Electromed (NYSE:ELMD) Rating Lowered to Buy at StockNews.com

Electromed (NYSE:ELMD) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Wednesday.

Electromed Trading Down 2.5 %

ELMD opened at $28.63 on Wednesday. The company’s 50 day moving average is $31.40 and its 200 day moving average is $25.17. The company has a market cap of $245.07 million, a price-to-earnings ratio of 38.17 and a beta of 0.33. Electromed has a 12-month low of $13.74 and a 12-month high of $35.56.

Insider Activity

In other news, Director Kathleen Skarvan sold 8,640 shares of Electromed stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $32.25, for a total transaction of $278,640.00. Following the transaction, the director now directly owns 71,576 shares of the company’s stock, valued at $2,308,326. The trade was a 10.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Andrew Summers sold 12,731 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $29.98, for a total value of $381,675.38. Following the transaction, the director now owns 165,755 shares of the company’s stock, valued at approximately $4,969,334.90. This trade represents a 7.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 77,788 shares of company stock valued at $2,326,350 in the last 90 days. Company insiders own 14.00% of the company’s stock.

Institutional Trading of Electromed

A number of hedge funds and other institutional investors have recently modified their holdings of ELMD. Arrowstreet Capital Limited Partnership lifted its stake in shares of Electromed by 261.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 114,579 shares of the company’s stock valued at $3,386,000 after buying an additional 82,839 shares in the last quarter. Hunter Associates Investment Management LLC lifted its position in shares of Electromed by 12.3% in the third quarter. Hunter Associates Investment Management LLC now owns 102,450 shares of the company’s stock valued at $2,199,000 after acquiring an additional 11,250 shares in the last quarter. Northern Trust Corp lifted its position in shares of Electromed by 14.1% in the fourth quarter. Northern Trust Corp now owns 65,350 shares of the company’s stock valued at $1,931,000 after acquiring an additional 8,086 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Electromed in the fourth quarter worth about $1,760,000. Finally, Susquehanna International Group LLP grew its position in shares of Electromed by 121.8% during the fourth quarter. Susquehanna International Group LLP now owns 56,726 shares of the company’s stock worth $1,676,000 after purchasing an additional 31,148 shares in the last quarter. 40.82% of the stock is owned by hedge funds and other institutional investors.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.